¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø Ç÷¾×Á¾¾ç³»°ú ÀåÁØÈ£ ±³¼ö°¡ 15ÀϺÎÅÍ 19ÀϱîÁö Àεµ³×½Ã¾Æ, ¸»·¹À̽þÆ, ű¹ µî µ¿³²¾Æ 3°³±¹ ÃÊûÀ¸·Î ÇöÁö¸¦ ¹æ¹®ÇØ °ñ¼öÇü¼ºÀÌ»óÁõÈıº Ä¡·á¿¡ °üÇÑ ÃÖ½ÅÁö°ßÀ» ÃÊû°¿¬Çß´Ù.
ÀåÁØÈ£ ±³¼ö´Â 3¿ù 15ÀÏ Àεµ³×½Ã¾Æ ÀÚÄ«¸£Å¸¿¡¼ °ñ¼öÇü¼ºÀÌ»óÁõÈıº ¿öÅ·ÆÄƼ(MDS working party) ÃÊûÀ¸·Î ‘Focus on epigenetic treatment and patient management’¸¦ ÁÖÁ¦·Î °¿¬ÇßÀ¸¸ç, 3¿ù 17ÀÏ ¸»·¹À̽þƿ¡¼´Â ‘Korean experience in epigenetic therapy’¸¦ ÁÖÁ¦·Î, 3¿ù 19ÀÏ Å±¹¿¡¼´Â ‘Hypomethylating agents improves myeoldysplastic syndrome treatment’ ÁÖÁ¦·Î ÃÊû°¿¬À» ÁøÇàÇß´Ù.
Àå ±³¼ö´Â À̹ø µ¿³²¾Æ 3±¹ ¼øȸ ÃÊû°¿¬À» ÅëÇØ ±×µ¿¾È °ñ¼öÇü¼ºÀÌ»óÁõÈıº(myeoldysplastic syndrome)ÀÇ Ç³ºÎÇÑ ÀÓ»ó°æÇèÀ» ÇöÁö ±¹°¡ ÀÇ·áÁø°ú °øÀ¯ÇÏ°í ÃֽŠġ·á¹ý µîÀ» °¿¬ÇÔÀ¸·Î½á ¿ì¸®³ª¶ó ÀÇÇмöÁØÀÇ À§»óÀ» ³Î¸® ¾Ë¸®´Âµ¥ Å« ±â¿©¸¦ ÇÑ °ÍÀ¸·Î Æò°¡¹Þ°í ÀÖ´Ù.
ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.